Sol-Gel Technologies Ltd. (SLGL) stock
SLGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 19, 2026Score 10/30
$52.83−2.13 (-3.88%)
Close on Nov 17, 2026Market cap $147.19MP/E –Yield –
Sol-Gel Technologies r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $22.80M, up 28.1% from the year before. Over ten years it grew 12.2% a year on average. The highest annual figure on record is $40.58M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.80M | +28.1% |
| FY2024 | Dec 31, 2024 | $17.80M | -24.4% |
| FY2023 | Dec 31, 2023 | $23.54M | +85.6% |
| FY2022 | Dec 31, 2022 | $12.68M | -37.8% |
| FY2021 | Dec 31, 2021 | $20.38M | -27.0% |
| FY2020 | Dec 31, 2020 | $27.91M | -31.2% |
| FY2019 | Dec 31, 2019 | $40.58M | +44.2% |
| FY2018 | Dec 31, 2018 | $28.15M | +9.1% |
| FY2017 | Dec 31, 2017 | $25.81M | +51.6% |
| FY2016 | Dec 31, 2016 | $17.02M | +137.0% |
| FY2015 | Dec 31, 2015 | $7.18M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.72M | +56.3% |
| Q2 FY2025 | Jun 30, 2025 | $4.65M | -33.0% |
| Q2 FY2024 | Jun 30, 2024 | $2.44M | -62.2% |
| Q2 FY2023 | Jun 30, 2023 | $5.31M | -53.6% |
| Q2 FY2022 | Jun 30, 2022 | $2.38M | -59.1% |
| Q2 FY2021 | Jun 30, 2021 | $6.93M | – |
| Q2 FY2020 | Jun 30, 2020 | $6.45M | – |
| Q2 FY2019 | Jun 30, 2019 | $11.44M | – |
| Q2 FY2018 | Jun 30, 2018 | $5.82M | – |
See a number that looks wrong?